FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215618401> ?p ?o ?g. }

• W3215618401 endingPage "185" @default.
• W3215618401 startingPage "175" @default.
• W3215618401 abstract "Synovial sarcoma (SS) is characterized by local invasiveness and a propensity to develop distant metastases. Current treatment for pediatric patients is based on the strategy used by the two main international groups, the Children's Oncology Group (COG) and the European group (EpSSG). Overall survival (OS) and event free survival (EFS) vary according to different publications; however, they tend to be dismal in initially metastatic patients, as well as relapsed patients. To describe the clinical, histopathological, molecular findings and outcome in a series of 22 pediatric patients treated at our institution over 15 years. A retrospective, descriptive study in patients with a histopathological or molecular diagnosis of SS between December 2005 and August 2019, treated according to the EpSSGNRSTS 2005 protocol. Median age at diagnosis was 138.1 months, 32.1% presented with a primary axial site, and 68% with a tumor larger than 5 cm. Initial metastatic disease was seen in 22.7%. Of initially localized patients, 70.6% were classified as high-risk. Chemotherapy was administered to 91% of our patients and 77.2% received radiotherapy. The 3-5- and 10-year OS and EFS was 66%, 58.7% and 48.9%, and 57%, 33%, 22.2% respectively. Localized patients had a 5- and 10-year OS of 73.3% and 61.1%, versus 40% and 0% in metastatic disease, respectively. The only statistically significant factors were presence of metastasis, tumor size and IRS group. Tumor relapse was seen in 31.8% of patients. Only patients with local recurrence that achieved a complete surgery are alive without disease. Treatment schemes after recurrence or progression included a combination of gemcitabine-docetaxel, vincristine-irinotecan-temozolomide, kinase tyrosine inhibitors, and metronomic therapy with cyclophosphamide or etoposide. A long progression free survival of 14 months was observed with etoposide. Although the sample size was not large enough to draw robust conclusions, in our series, OS and EFS rates were found to be lower than those reported in other studies, probably related to unfavorable prognostic factors, including a high incidence of metastasis and tumors larger than 5 cm. New therapeutic strategies are needed to improve outcome, especially in metastatic and relapsed disease. In addition, assessing the role of maintenance therapy in larger numbers of patients and broadening the use of metronomic chemotherapy would be necessary." @default.
• W3215618401 created "2021-12-06" @default.
• W3215618401 creator A5001337036 @default.
• W3215618401 creator A5022936031 @default.
• W3215618401 creator A5039818076 @default.
• W3215618401 creator A5040779293 @default.
• W3215618401 creator A5042648342 @default.
• W3215618401 creator A5049436442 @default.
• W3215618401 creator A5060020595 @default.
• W3215618401 creator A5071785989 @default.
• W3215618401 creator A5085851539 @default.
• W3215618401 creator A5088346031 @default.
• W3215618401 date "2021-12-01" @default.
• W3215618401 modified "2023-10-18" @default.
• W3215618401 title "Synovial sarcoma in children: A 15-YEAR experience at a tertiary pediatric center in Argentina" @default.
• W3215618401 cites W1966107654 @default.
• W3215618401 cites W1977144004 @default.
• W3215618401 cites W1978776545 @default.
• W3215618401 cites W1988505549 @default.
• W3215618401 cites W2009220618 @default.
• W3215618401 cites W2013696012 @default.
• W3215618401 cites W2021904420 @default.
• W3215618401 cites W2073965542 @default.
• W3215618401 cites W2076391562 @default.
• W3215618401 cites W2086371526 @default.
• W3215618401 cites W2101776780 @default.
• W3215618401 cites W2101969345 @default.
• W3215618401 cites W2102461238 @default.
• W3215618401 cites W2119868039 @default.
• W3215618401 cites W2134158216 @default.
• W3215618401 cites W2134549022 @default.
• W3215618401 cites W2160028990 @default.
• W3215618401 cites W2160252880 @default.
• W3215618401 cites W2161602451 @default.
• W3215618401 cites W2165967358 @default.
• W3215618401 cites W2308671100 @default.
• W3215618401 cites W2515549731 @default.
• W3215618401 cites W2518778637 @default.
• W3215618401 cites W2602570683 @default.
• W3215618401 cites W2605336082 @default.
• W3215618401 cites W2753484208 @default.
• W3215618401 cites W2773879876 @default.
• W3215618401 cites W2792378400 @default.
• W3215618401 cites W2800425854 @default.
• W3215618401 cites W2884795958 @default.
• W3215618401 cites W2888576028 @default.
• W3215618401 cites W2897295977 @default.
• W3215618401 cites W2922332121 @default.
• W3215618401 cites W2989695520 @default.
• W3215618401 cites W3000719117 @default.
• W3215618401 cites W3033206180 @default.
• W3215618401 cites W3038916963 @default.
• W3215618401 doi "https://doi.org/10.1016/j.phoj.2021.11.008" @default.
• W3215618401 hasPublicationYear "2021" @default.
• W3215618401 type Work @default.
• W3215618401 sameAs 3215618401 @default.
• W3215618401 citedByCount "1" @default.
• W3215618401 countsByYear W32156184012022 @default.
• W3215618401 crossrefType "journal-article" @default.
• W3215618401 hasAuthorship W3215618401A5001337036 @default.
• W3215618401 hasAuthorship W3215618401A5022936031 @default.
• W3215618401 hasAuthorship W3215618401A5039818076 @default.
• W3215618401 hasAuthorship W3215618401A5040779293 @default.
• W3215618401 hasAuthorship W3215618401A5042648342 @default.
• W3215618401 hasAuthorship W3215618401A5049436442 @default.
• W3215618401 hasAuthorship W3215618401A5060020595 @default.
• W3215618401 hasAuthorship W3215618401A5071785989 @default.
• W3215618401 hasAuthorship W3215618401A5085851539 @default.
• W3215618401 hasAuthorship W3215618401A5088346031 @default.
• W3215618401 hasBestOaLocation W32156184011 @default.
• W3215618401 hasConcept C121608353 @default.
• W3215618401 hasConcept C126322002 @default.
• W3215618401 hasConcept C141071460 @default.
• W3215618401 hasConcept C142724271 @default.
• W3215618401 hasConcept C143998085 @default.
• W3215618401 hasConcept C154945302 @default.
• W3215618401 hasConcept C167135981 @default.
• W3215618401 hasConcept C2776694085 @default.
• W3215618401 hasConcept C2776910622 @default.
• W3215618401 hasConcept C2778162587 @default.
• W3215618401 hasConcept C2778256501 @default.
• W3215618401 hasConcept C2779013556 @default.
• W3215618401 hasConcept C2779134260 @default.
• W3215618401 hasConcept C2780073493 @default.
• W3215618401 hasConcept C2780192828 @default.
• W3215618401 hasConcept C2909143077 @default.
• W3215618401 hasConcept C2991842025 @default.
• W3215618401 hasConcept C3019926457 @default.
• W3215618401 hasConcept C41008148 @default.
• W3215618401 hasConcept C4661277 @default.
• W3215618401 hasConcept C509974204 @default.
• W3215618401 hasConcept C71924100 @default.
• W3215618401 hasConceptScore W3215618401C121608353 @default.
• W3215618401 hasConceptScore W3215618401C126322002 @default.
• W3215618401 hasConceptScore W3215618401C141071460 @default.
• W3215618401 hasConceptScore W3215618401C142724271 @default.
• W3215618401 hasConceptScore W3215618401C143998085 @default.
• W3215618401 hasConceptScore W3215618401C154945302 @default.

• next